Skip to content
Screener

Schrodinger SDGR Restricted Cash

Restricted Cash at other companies

Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$5.39M+73.4%
Absci Corporation logo
Absci CorporationABSI
$1.05M-93.5%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$25M0.0%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$1.34M-40.8%
Sutro Biopharma logo
Sutro BiopharmaSTRO
$858K0.0%
Septerna, Inc. logo
Septerna, Inc.SEPN
$905K0.0%

Other financials

Income statement

See full
Revenue$58.9M+7.5%
Gross profit$32.4M+24.0%
Operating income-$41.5M+21.5%
Net income$6.0M+114%
EPS (diluted)$0.08+114%

Balance sheet

See full
Cash & equivalents$292.9M+26.3%
Total debt$108.0M-5.5%
Total equity$329.0M-4.1%
Total assets$640.4M-7.0%

Cash flow

See full
Operating cash flow-$34.1M
CapEx$362.0K+15.3%
Free cash flow-$34.4M

Valuation

See full
Market cap$1.4B+2.4%
Enterprise value$1.22B-2.7%
P/S5.4×-0.3×

Profitability

See full
Gross margin56.9%-1.6pp
Operating margin-59.2%-12.6pp
Net margin-68.5%
FCF margin9.6%+5.1pp

Returns & leverage

See full
Return on equity-45.7%
Debt / equity0.3×0.0×
Current ratio2.7×-0.6×

Where this comes from

Reported directly by Schrodinger in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.

The source filing: Schrodinger’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:08 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001490978-26-000068
AssetsJune 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents$287,853$230,517
Restricted cash (includes related party amounts of $63 and $72, respectively)5,0636,868
Marketable securities125,886164,947
Accounts receivable, net of allowance for doubtful accounts of $265 and $440 (includes related party amounts of $5,000 and $100, respectively)21,39183,041
Unbilled and other receivables, net of allowance for unbilled receivables of $140 and $14019,73321,352
Prepaid expenses10,54912,540
Total current assets470,475519,265

Item 1. Financial Statements.

FAQ

What is Schrodinger's restricted cash?
Schrodinger (SDGR) reported restricted cash of $5.06M in Q2 2026.
How has Schrodinger's restricted cash changed year-over-year?
Schrodinger's restricted cash decreased by 58.1% year-over-year, from $12.08M to $5.06M.
What is the long-term trend for Schrodinger's restricted cash?
Over 5 years (2020 to 2025), Schrodinger's restricted cash has grown at a 68.9% compound annual growth rate (CAGR), from $500K to $6.87M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Ask your AI about Schrodinger's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude